Table 1.

Characteristics of 16 patients with infections by Pseudomonas mendocina: site of infection, antimicrobial resistance, treatment and outcomes. Values show cases among patients with available data.

Characteristic	Value
Male, n (%)	12 out of 16 (75%)
Age, mean (+/− SD) in years	53.5 (19.9)
Medical History
HIV infection, n (%)	1 out of 16 (6.3%)
Central venous catheter, n (%)	1 out of 16 (6.3%)
Previous antibiotic use, n (%)	1 out of 16 (6.3%)
No known predisposing factors, n (%)	7 out of 16 (43.8%)
Site of Infection
Infective endocarditis, n (%)	4 out of 16 (25%)
Central nervous system infection, n (%)	4 out of 16 (25%)
Skin and soft tissue infections, n (%)	3 out of 16 (18.8%)
Bacteremia (without endocarditis), n (%)	2 out of 16 (12.5%)
Musculoskeletal infections, n (%)	2 out of 16 (12.5%)
Peritoneal dialysis-associated peritonitis, n (%)	1 out of 16 (6.3%)
Data on Infection
Presence of fever, n (%)	7 out of 10 (70%)
Presence of sepsis, n (%)	4 out of 9 (44.4%)
Antimicrobial Resistance
Ampicillin resistance, n (%)	4 out of 5 (80%)
Co-trimoxazole resistance, n (%)	1 out of 3 (33.3%)
Carbapenem resistance, n (%)	1 out of 10 (10%)
Third or fourth generation cephalosporin resistance, n (%)	0 out of 11 (0%)
Aminoglycoside resistance, n (%)	0 out of 10 (0%)
Quinolone resistance, n (%)	0 out of 7 (0%)
Piperacillin–tazobactam resistance, n (%)	0 out of 6 (0%)
Colistin resistance, n (%)	0 out of 1 (0%)
Treatment of P. mendocina IE
Third or fourth generation cephalosporins, n (%)	8 out of 15 (53.3%)
Quinolones, n (%)	5 out of 15 (33.3%)
Aminoglycosides, n (%)	3 out of 15 (20%)
Carbapenems, n (%)	2 out of 15 (13.3%)
Colistin, n (%)	2 out of 15 (13.3%)
Piperacillin–tazobactam, n (%)	1 out of 15 (6.7%)
Aminopenicillins, n (%)	1 out of 15 (6.7%)
Co-trimoxazole, n (%)	1 out of 15 (6.7%)
Outcome
Clinical cure, n (%)	14 out of 15 (93.3%)
Deaths due to the infection, n (%)	0 out of 15 (0%)
Deaths overall, n (%)	1 out of 15 (6.7%)

SD: standard deviation; HIV: human immunodeficiency virus.